Comparison of 68Ga-PSMA-11 and 18F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence

Conclusion: This case series suggests improved detection rates for 68Ga-PSMA-11 PET/CT when compared with 18F-fluciclovine PET/CT in patients with recurrent PCa. Prospective trials designed to directly compare the two should be initiated.

Source: Journal of Nuclear Medicine - May 1, 2018 Category: Nuclear Medicine Authors: Calais, J., Fendler, W. P., Herrmann, K., Eiber, M., Ceci, F. Tags: Clinical Source Type: research